GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Universal Ibogaine Inc (TSXV:IBO) » Definitions » Debt-to-EBITDA

Universal Ibogaine (TSXV:IBO) Debt-to-EBITDA : -7.06 (As of Jan. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Universal Ibogaine Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Universal Ibogaine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.13 Mil. Universal Ibogaine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$2.67 Mil. Universal Ibogaine's annualized EBITDA for the quarter that ended in Jan. 2024 was C$-0.40 Mil. Universal Ibogaine's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 was -7.06.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Universal Ibogaine's Debt-to-EBITDA or its related term are showing as below:

TSXV:IBO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.97   Med: -0.78   Max: -0.17
Current: -3.97

During the past 7 years, the highest Debt-to-EBITDA Ratio of Universal Ibogaine was -0.17. The lowest was -3.97. And the median was -0.78.

TSXV:IBO's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs TSXV:IBO: -3.97

Universal Ibogaine Debt-to-EBITDA Historical Data

The historical data trend for Universal Ibogaine's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universal Ibogaine Debt-to-EBITDA Chart

Universal Ibogaine Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Jul22 Jul23
Debt-to-EBITDA
Get a 7-Day Free Trial - - -0.78 -0.17 -1.43

Universal Ibogaine Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.83 -1.85 -4.18 -8.82 -7.06

Competitive Comparison of Universal Ibogaine's Debt-to-EBITDA

For the Biotechnology subindustry, Universal Ibogaine's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Universal Ibogaine's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's Debt-to-EBITDA falls into.



Universal Ibogaine Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Universal Ibogaine's Debt-to-EBITDA for the fiscal year that ended in Jul. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.815 + 0.962) / -1.941
=-1.43

Universal Ibogaine's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.131 + 2.666) / -0.396
=-7.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jan. 2024) EBITDA data.


Universal Ibogaine  (TSXV:IBO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Universal Ibogaine Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Universal Ibogaine's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Universal Ibogaine (TSXV:IBO) Business Description

Traded in Other Exchanges
Address
400 3rd Avenue South west, Suite 1470, Calgary, AB, CAN, T2P 4H2
Universal Ibogaine Inc develops a platform of addiction treatment clinics, which use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants. It runs addiction clinics it has a research partner clinic in Mexico.

Universal Ibogaine (TSXV:IBO) Headlines

No Headlines